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Abstract
Introduction: The pathophysiology of sepsis consists of two phases. A first phase characterized by a substantial
increase of pro-inflammatory mediators including cytokines and systemic inflammatory markers, and a second
phase (immunoparalysis, immunodysregulation) associated with the rise of anti-inflammatory mediators. In this
study we prospectively analyzed 52 consecutive patients with diagnosis of systemic inflammatory response
syndrome (SIRS) at hospital admission to evaluate prognostic and early diagnostic performance of interleukin-10
(IL-10), soluble CD25 (sCD25) and interferon-g (IFN-g) and to confirm the prognostic accuracy of the sequential
organ failure assessment (SOFA) score.
Methods: Patients were divided in two groups (group 1, n = 28 patients with bacteremic SIRS and group 2, n =
24 patients with non-bacteremic SIRS) and then stratified into survivors (n = 39) and nonsurvivors (n = 13). Serum
markers were evaluated on the day of hospital admission (D-1) and on the 7th day of hospital stay (D-7).
Concentration of sCD25 was evaluated by a sandwich ELISA kit. Levels of IL-10 and IFN-g were quantified by a
cytokine biochip array by the evidence investigator analyzer. Differences between groups were established by the
Mann-Whitney test. Accuracy, sensitivity and specificity of diagnostic markers were evaluated by the receiver-
operating characteristic curve analysis. Multivariate analysis was carried out to evaluate whether studied biomarkers
are independent predictors of poor outcome in prognosis, and of bacteremic SIRS in diagnosis.
Results: IL-10, sCD25 and SOFA scores of survivors and nonsurvivors were significantly different both at D-1 (P =
0.0014; P = 0.014 and P = 0.0311 respectively) and at D-7 (P = 0.0002, P = 0.014 and P = 0.0012 respectively).
Between the above groups IFN-g level was significantly different only at D-7 (P = 0.0013). Moreover IL-10 and
sCD25 were significantly higher in bacteremic versus non-bacteremic SIRS patients at D-1 and at D-7 (P < 0.05).
IFN-g values showed a significant decrease (P < 0.05) in patients of group 1 only at D-7. The diagnostic accuracy of
IL-10 and sCD25 was confirmed by the analysis of the AUROCC at D-1 and D-7 respectively. Multivariate analysis
revealed that sCD25 and IL-10 are independent predictors of a poor outcome for our patients during the first day
of hospital admission.
Conclusions: IL-10 and sCD25 gave a significant contribution to prognostic evaluation and early diagnosis of
bacteremic SIRS. SOFA score appeared to be a reliable prognostic tool in this subset of patients.
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Introduction
Sepsis is a severe syndrome with significant morbidity
and mortality [1]. The poor knowledge of pathophysiol-
ogy, the lack of early diagnostic markers and the inabil-
ity to timely stratify patients with reliable prognostic
tools might account for the frequent delay in therapeu-
tic treatment [2]. Although innate immunity and sys-
temic inflammation are generally regarded as a first-line
defense against microbial invasion, an overwhelming
immune/inflammatory response might contribute to
sepsis-related complications [3].
Recently two phases have been identified in the patho-
physiology of sepsis: a first phase characterized by a sub-
stantial increase of the pro-inflammatory mediators
including cytokines, and systemic inflammatory markers,
for example, procalcitonin (PCT) and C-reactive protein
(CRP), and a second phase (immunoparalysis, immuno-
dysregulation) with the rise of anti-inflammatory media-
tors [4,5]. The amplitude of the response needs to be
fine-tuned in order to achieve effective clearance of
pathogens, while limiting the amount of inflammation
and avoiding toxicity and collateral tissue damage [6].
Although several candidates have been investigated
regarding the anti-inflammatory cascade, the most con-
sistent data concern IL-10 [5]. More recently the soluble
form of CD25 (sCD25), a Treg lymphocyte antigen, has
been suggested as a marker of the immunosuppressive
phase of sepsis [7].
Surgical stress, anesthesia and/or analog sedation can
alter and/or compromise the immune response and may
disturb the balance of human pro-inflammatory and anti-
inflammatory cytokines [4-6]. It has been reported that a
significant enhancement of IFN-g and sCD25 release in
lipopolysaccharide (LPS)-stimulated whole blood cultures
after induction of anesthesia [7]. High IL-10 levels have
been associated with a worse outcome after severe sepsis,
whereas TNF-a and IL-6 have not [5].
PCT and CRP have already been identified as useful
markers of systemic inflammation due to infective
(mainly bacterial) agents [8-15]. An effective immune
response against bacterial infections requires the devel-
opment of a T helper (Th)1 response that is associated
with the release of IFN-g [16]. A recent paper [17] sug-
gested a very early role of the adaptive immune system
in the pathogenesis of sepsis, hypothesizing that Th1
and Th17 T cells may serve to increase the overall
inflammatory response during sepsis. All the above dis-
cussed mediators of sepsis pathophysiology might be
exploited to gain useful data on the prognosis and early
diagnosis of systemic inflammatory response syndrome
(SIRS) patients. However, other reports [8,14,15] have
questioned the role of PCT, CRP and some cytokines in
the clinical management of critically ill patients.
In this scenario the first aim of our study was to
investigate the prognostic role of specific mediators (IL-
10, sCD25 and IFN-g) and of the Sequential Organ Fail-
ure Assessment (SOFA) score [18] in bacteremic and
non-bacteremic SIRS, while the second aim was to
assess the early diagnostic role of the above mentioned
mediators.
Materials and methods
Patients and study design
Fifty-two patients admitted to the University Hospital of
Catanzaro (Italy) with diagnosis of SIRS have been
sequentially enrolled from May 2008 to April 2009.
Twelve healthy volunteers have been enrolled to obtain
baseline serum levels of the mediators. We divided
patients in two groups: bacteremic SIRS patients (group
1, n = 28) with positive blood cultures, and non-bactere-
mic SIRS patients (group 2, n = 24) with persistently
negative blood cultures. Most of the included patients
(28/52) were submitted to on-pump cardiac surgery.
Serum levels have been obtained at D-1 (first day of
hospital admission) and D-7 (seventh day of hospital
stay). At the end of the observation, patients were strati-
fied into survivors (n = 39) and nonsurvivors (n = 13).
The observational prospective study protocol and the
use of volunteers was approved by the Catanzaro Uni-
versity Hospital Ethical Committee. Informed consent
was obtained by the patients or by their relatives.
Inclusion and exclusion criteria
The subjects were enrolled if the diagnosis of SIRS was
made. SIRS was defined as two or more of the following: i)
hypothermia or fever (temperature < 36°C or > 38.5°C,
respectively); ii) tachycardia (> 90 beats/minute); iii)
tachypnea (> 20 breaths/minute or PaCO2 < 32 mmHg
when on mechanical ventilation); iv) leukocytosis (>
12,000 white blood cells (WBCs)/mm3), leukopenia (<
4,000 WBCs/mm3), or an increase in the number of
immature band forms (> 10%) [19]. Subjects under 18
years of age and patients treated with immunosuppressive
drugs were excluded from the study. Severity of illness
was defined using the SOFA score.
Laboratory assays
Venous blood samples were obtained from each patient
within 6 h from the first day of hospital admission (D-
1) and at the seventh day of hospital stay (D-7). Serum
was separated, divided in aliquots and immediately fro-
zen (-80 C°) until the time of the assay. Concentrations
of sCD25 were evaluated by sandwich ELISA kits,
according to the manufacturer’s recommendations
(Bender MedSystems, Vienna, Austria). Levels of IL-10
and IFN-g were quantified by a cytokine biochip array
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on the Evidence Investigator analyser following the
manufacturer’s instructions (Randox Laboratories Ltd.,
Crumlin, UK).
Samples for blood cultures were processed with a
BacT/Alert 3D system. This system uses blood culture
bottles, which include resins that adsorb and neutralize
antibiotics contained in the patient’s sample. In all
blood cultures, growth was usually detected after an
incubation of 24 to 36 h. Subcultures on Columbia
blood agar, as well as bacteriological stains were carried
out on both the direct sampling from the bottle and
from the subculture. The microorganisms were identi-
fied through the typical Gram stain morphology and the
standard clinical microbiology techniques. Isolate identi-
fication was confirmed using specific cards processed
by a VITEK 2 instrument (bioMerieux, Marcy l’Étoile }
France).
Endpoints
The primary endpoint was to investigate the prognostic
role of IL-10, sCD25, IFN-g and SOFA score in bacteremic
and non-bacteremic SIRS, while the secondary endpoint
was to assess the early diagnostic value of sCD25, IL-10
and IFN-g in the same patient population.
Statistics
Patients were first stratified based on culture results
(culture-positive and culture-negative) then subsequently
divided into survivors and nonsurvivors. Statistically sig-
nificant differences between groups were established by
the Mann-Whitney test.
The receiver-operating characteristic (ROC) curve was
used to evaluate diagnostic accuracy defined by the area
under the ROC curve (AUROCC) of the analyzed bio-
markers and to determine the sensitivity and specificity
at cut-off values selected by Youden index J. The 95%
CI for the AUROCC values were estimated using the
conservative bootstrap bias-corrected and accelerated
method to obtain more accurate intervals [20]. The
accuracy of the AUROCC test was defined as: excellent
(0.9 to 1.0); good/fair (0.7 to 0.9); poor (0.6 to 0.7); and
not useful (< 0.6). Cytokine levels below the limit of
detection were assigned a value that was equal to half of
the lower limit of detection in the standard curve [21].
Biomarkers evaluated for poor prognosis, as well as for
the diagnosis of bacteremic SIRS were analyzed inde-
pendently using multivariate logistic regression analysis.
The analyses were performed using Graph-Pad 4.0
(Graph-Pad Software Inc., San Diego, CA, USA), SPSS
14.0 software (SPSS, Chicago, IL, USA) and MedCalc
11.1.1.0 Software (BVBA, Mariakerke, Belgium). Results
are presented as means ± standard error of the mean
(SEM) (unless otherwise stated); P < 0.05 was consid-
ered significant.
Results
We enrolled 52 patients (mean age 64 years); 28 patients
were culture-positive and 24 were culture-negative
(Table 1). In the bacteremic group, the following bac-
teria were identified: Staphylococcus spp. (five isolates),
Pseudomonas spp. (four isolates), Candida spp. (three
isolates), Escherichia coli (five isolates), Klebsiella spp.
(three isolates), Enterococcus faecium (two isolates), She-
wanella putrefaciens (one isolate), Bacteroides capillosus
(one isolate), Listeria monocytogenes (one isolate), Steno-
trophomonas maltophilia (four isolates), Burkholderia
cepacia (one isolate), Staphylococcus aureus (two iso-
lates). A small number of cultures had more than one
isolate. Among the bacterial isolates, we found 19
Gram-negative and 11 Gram-positive microorganisms.
Prognostic roles of markers
As expected, the SOFA scores were significantly higher
among nonsurvivors in comparison to survivors at D-1
(P = 0.0311) and D-7 (P = 0.0012) (Figure 1A).











Mean age, years) 64.07 65.07 64.68
Male/female 39/13 13/15 16/8
Survivors/non-survivors 39/13 16/12 23/1




Cardiac surgery of the valvular
systems
8 3 5
Combined cardiac surgery 9 5 4
Type I aortic dissection 2 1 1
Cardiogenic pulmonary oedema 5 4 1
Total pneumonectomy 3 2 1
Adult respiratory distress syndrome
(ARDS)
2 0 2
Subarachnoid hemorrage 2 2 0
Transient ischemic attack 1 0 1
Lateral Amiotrophic Sclerosis 1 0 1
Meningioma 1 0 1
Meningoencephalitis 1 1 0
Total laringectomy 1 1 0
Total gastrectomy 1 1 0
Post-cardiac arrest recovery 1 0 1
Pneumonia 1 1 0
Polytrauma 1 0 1
Hemoperitoneum 1 1 0
Shock 2 1 1
Results are presented as number of patients. SIRS, systemic inflammatory
response syndrome.
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Serum levels of IL-10 were significantly higher in non-
survivors at both D-1 (P = 0.0014) and D-7 (P = 0.0002)
(Figure 1B). Similarly, sCD25 exhibited a significant
increase among nonsurvivors at both D-1 (P = 0.014)
and D-7 (P = 0.014) (Figure 1D). On the contrary
between the above groups IFN-g level was significantly
reduced (Figure 1C) in nonsurvivors at D-7 (P =
0.0013). PCT serum levels were also significantly higher
in nonsurvivors, but only at D-7 (P = 0.04) (data not
shown).
A 25.0% crude mortality was observed in the whole
study, with 42.9% in the bacteremic group (Table 1).
ROC analysis has been carried out on the studied bio-
marker data stratified in survivors and non-survivors
(Figure 2) to estimate the prognostic value of such bio-
markers in terms of the AUROC and the significance
AUROC, and the sensitivity, specificity, positive likeli-
hood ratio and negative likelihood ratio. The AUROC of
all the biomarkers evaluated was associated with a sig-
nificant level of P (< 0.05) (Table 2).
In the multivariate analysis of the logistic regression
model, using the SOFA score for correction of disease
severity, sCD25 and IL-10 were the variables with statis-
tically significant relative risks at time D-1, and there-
fore could be considered to be independent predictors
of a poor outcome for our patients during the first day
of hospital admission (Table 3).
Diagnostic role of markers
The trend of IL-10 levels showed a significant increase
(P < 0.05) in the group of bacteremic patients at D-1
and D-7 (Figure 3A). AUROCC values at both of the
time intervals were fairly high, as well as their sensitivity
and specificity (Table 4).
Similarly sCD25 serum values were significantly higher
(P < 0.05) in the bacteremic group at both D-1 and D-7
(Figure 3B). The values of AUROCC showed high sensi-
tivity and specificity at D-1 and D-7 with significant
accuracy for sCD25 (Table 4). IFN-g levels were signifi-







Figure 1 Sequential Organ Failure Assessment (SOFA) score, IL-10, IFN-g and sCD25 in non-survivors and survivors SIRS patients.
SOFA score values (A), as well as IL-10 (B), IFN-g (C) and sCD25 (D) serum levels observed in our patients stratified in non-survivors (n = 13) and
survivors (n = 39) at the time of hospital presentation (D-1) and at the end of first week of hospital stay (D-7). Data are means ± standard
error of the mean of the observations from the above reported number of patients. *P < 0.05 vs survivors at the same time point
(Mann-Whitney test).
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patients at D-7 only (Figure 3C), when the accuracy of
the AUROCC of the biomarker was also significant (P <
0.05). Serum levels of PCT were significantly higher in
bacteremic patients at D-1 and D-7 compared to non-
infectious SIRS (P < 0.05) (Figure 3D).
The mean values of serum levels of IFN-g and IL-10
in healthy volunteers were 1.57 ± 0.52 pg/ml and 0.56 ±
0.16 pg/ml respectively, while sCD25 concentration was
not measurable. A statistically significant difference (P <
0.05) was observed between levels of the measurable
markers between the controls and bacteremic patients.
The ROC curves of diagnostic biomarkers evaluated at
D-1 and at D-7 are showed in panel A and B respec-
tively of Figure 4. The multivariate analysis of diagnostic
biomarkers is reported in Table 5; none of the investi-
gated biomarkers appeared to be independent predictors
of bacteremic SIRS in our patients.
Serum levels of PCT were analyzed and levels of the
marker were observed at several time points (0, 24, 48,
72, and 168 hours after admission) in bacteremic survi-
vors and nonsurvivors (Figure 5). Only during the hospi-
tal admission day (0 h) was there a significant (P =
0.0075) difference between the above subset of bactere-
mic patients. Indeed bacteremic survivors exhibited a
higher level of PCT until 72 h after admission, although
PCT was only significant on hospital admission day.
Discussion
Taken together our data suggest that IL-10 and sCD25
may be considered as relevant markers of prognosis, in
addition to the SOFA score in this specific clinical
context. Moreover IL-10 and sCD25 might have a major
role in the early diagnosis of bacteremic SIRS. Until
now inconclusive attempts have been made to identify
an optimal marker of sepsis [13,14]. The ideal parameter
should be sensitive enough to perceive the presence of
pathogens with a minimal host response and at the
same time specific enough to distinguish between infec-
tious and non-infectious systemic inflammatory
response. Moreover it should be easily and rapidly avail-
able and finally it should be reliable from a prognostic
point of view [22].
The availability of a reliable marker for early diagnosis
is still an unsolved problem. Some reports have ques-
tioned the role of PCT, CRP and some cytokines for the
diagnosis and the prognosis of critically ill patients
[14,15]. A more recent article [23] showed a moderate
diagnostic performance of PCT, with mean values of
71% (95% CI 67 to 76%) for both sensitivity and specifi-
city, and AUROCC of 0.78 (95% CI 0.73 to 0.83). These
values are similar to our findings (0.80 for D-1 and 0.78
for D-7) but different from AUROCC values (0.92)
shown in other reports [24]. Moreover, our findings of
bacteremic survivors exhibiting a higher level of PCT in
comparison to bacteremic nonsurvivors until 72 h after
admission (although only significant was on hospital
admission day), probably warrant further assessment.
Our results showed a statistically non-significant
increase of IFN-g among bacteremic SIRS patients at D-
1 followed by a statistically significant decrease of
the same biomarker in this group of patients at D-7.
In accordance with our data, other authors showed a
A B 
Figure 2 Receiver-operating characteristic (ROC) analysis of prognostic biomarkers. ROC curves for IL-10 (blue line), sCD25 (yellow line),
IFN-g (red line), procalcitonin (PCT) (green line) and Sequential Organ Failure Assessment (SOFA) score (orange line) values, observed in our
patients stratified in nonsurvivors (n = 13) and survivors (n = 39) (used as controls for ROC analysis) either at the time of hospital admission (D-1)
(A) or at the end of first week of hospital stay (D-7) (B).
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non-significant increase of both IFN- g and its mRNA in
septic patients [25]. However, other data about the early
increase of IFN- g during sepsis and human experimen-
tal endotoxemia have been previously collected [26]. At
the same time, the significance of the IFN- g decrease in
late sepsis in both human [27] and animal settings [28]
has been confirmed. We could speculate that the
decrease of IFN- g values observed in this study may
indicate the beginning of compensatory antiinflamma-
tory response syndrome (CARS) [29] during the late
stage of sepsis.
Lymphocyte dysfunction has been related to profound
immune depression, eventually leading to septic shock
and poor outcome [30]. Lymphocyte subpopulations dif-
ferentially undergo apoptosis during sepsis with a high
resistance within the CD25+ subset [5]: in this context it
is therefore likely that these cells may give their sup-
pressive contribution through the release of sCD25 and
IL-10 [31]. Our findings on IL-10 demonstrate the prog-
nostic and diagnostic value of this cytokine in a specific
clinical scenario. Due to its anti-inflammatory and
immunosuppressive activity, IL-10 may initially control
the exaggerated pro-inflammatory wave of early media-
tors in sepsis; however persistent high levels of IL-10
can cause immunoparalysis and eventually lead to poor
outcome in septic shock [5]. A quite unexpected finding
of our study was the early increase of IL-10 and sCD25,
which should be associated with the late/immunosup-
pressive stage of sepsis according to current literature
[4,5]. Very recently Kasten et al. [17] underlined a very
early role of the adaptive immune system in the patho-
genesis of sepsis. Therefore, IL-10 and sCD25 should be
considered not only as late but also as early mediators
of bacteremic SIRS and sepsis. Enhanced concentrations
of IL-10 associated with a decrease of the IFN- g might
account for the delay in pathogen eradication during the
late stage of sepsis (immunoparalysis) [5]. An increase
Table 2 Performance of studied variables in predicting
mortality




IL-10 AUROCC 0.942 (0.81, 0.99) 0.971 (0.850, 0.99)
AUROCC significance P = 0.0001 P = 0.0001
Cutoff 3.05 3.40
Sensitivity 91.67 (61.5, 99.8) 100.00 (73.5,
100.0)
Specificity 86.96 (66.4, 97.2) 95.65 (78.1, 99.9)
Positive likelihood ratio 7.03 (2.4, 20.5) 23.00 (3.4, 156.4)
Negative likelihood
ratio
0.096 (0.01, 0.6) 0.00
sCD25 AUROCC 0.793 (0.62, 0.91) 0.861 (0.70, 0.95)
AUROCC significance P = 0.0047 P = 0.0001
Cutoff 19.9 20.4
Sensitivity 83.33 (51.6, 97.9) 91.67 (61.5, 99.8)
Specificity 91.30 (72.0, 98.9) 91.30 (72.0, 98.9)
Positive likelihood ratio 9.58 (2.5, 36.9) 10.54 (2.8, 40.1)
Negative likelihood
ratio
0.18 (0.05-0.7) 0.091 (0.01-0.6)




AUROCC significance P = 0.4447 P = 0.0011
Cut-off 9.00 5.79
Sensitivity 50.00 (21.1, 78.9) 66.67 (34.9, 90.1)
Specificity 86.96 (66.4, 97.2) 95.65 (78.1, 99.9)
Positive likelihood ratio 3.83 (1.2, 12.7) 15.33 (2.2, 108.7)
Negative likelihood
ratio
0.58 (0.3, 1.0) 0.35 (0.2, 0.8)




AUROCC significance P = 0.0027 P = 0.0001
Cutoff 0.35 0.87
Sensitivity 83.33 (51.6, 97.9) 75.00(42.8, 94.5)
Specificity 69.57 (47.1, 86.8) 95.65 (78.1, 99.9)
Positive likelihood ratio 2.74 (1.4, 5.3) 17.25 (2.5, 120.6)
Negative likelihood
ratio
0.24 (0.07, 0.9) 0.26 (0.10, 0.7)




AUROCC significance P = 0.0001 P = 0.0001
Cutoff 6 7
Sensitivity 83.33(51.6, 97.9) 100.00 (73.5,
100.0)
Specificity 86.96 (66.4, 97.2) 86.96 (66.4, 97.2)
Positive likelihood ratio 6.39 (2.2, 18.9) 7.67 (2.7, 22.0)
Negative likelihood
ratio
0.19 (0.05, 0.7) 0.00
Prognostic accuracy of IL-10, sCD25, IFN-g, procalcitonin (PCT) and Sequential
Organ Failure Assessment (SOFA) score evaluated by receiver-operating
characteristic (ROC) analysis carried out on samples obtained at the time of
hospital presentation (D-1) and at the end of first week of the hospital stay
(D-7), to estimate the pro- and anti-inflammatory mediators as prognostic
markers of poor outcome in critically ill patients. AUROCC, area under the
ROC curv
Table 3 Multivariate analysis of the factors associated
with prognosis of bacteremic patients with systemic
inflammatory response syndrome (SIRS)
Factor Odds ratio 95% (CI) P-value
IL-10 D-1 1.86 0.98, 3.52 < 0.05
D-7 2.06 0.14, 6.54 > 0.05
sCD25 D-1 1.12 1.01, 1.25 < 0.05
D-7 0.97 0.87, 1.09 > 0.05
IFN-g D-1 1.03 0.86, 1.23 > 0.05
D-7 0.54 0.19, 1.51 > 0.05
PCT D-1 6.53 0.06, 68.4 > 0.05
D-7 39.71 0.05, 315 > 0.05
PCT: procalcitonin.
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of soluble CD25 in the plasma of bacteremic compared
with non-bacteremic SIRS patients has been recently
reported [7]. In accordance with these reports our study
has highlighted the prognostic and early diagnostic
value of IL-10 and sCD25: we believe that in the near
future these markers could become valid tools for the
management of patients with bacteremic SIRS and
sepsis.
Limitations
Our study has several limitations. First of all this is an
observational prospective investigation with quite a
small sample size. The final results of microbiological
cultures are not necessarily representative of the rest of
the country or of other nations. The small sample size
is mainly due to missing data from many of our bactere-
mic and non-bacteremic SIRS patients, for whom
informed consensus was not obtained, or to lack of the
required sampling or of timely sampling carried out by
nurses. These patients were not included in the study.
Also the difficulties in finding SIRS patients with com-
parable age, sex and co-morbidities often made match-
ing difficult. Further limitation of our study is the small





Figure 3 IL-10, sCD25, IFN-g and procalcitonin (PCT) levels in bacteremic and non-bacteremic patients with systemic inflammatory
response syndrome (SIRS). Levels of IL-10 (A), sCD25 (B), IFN-g (C), and PCT (D) in serum samples of the bacteremic (culture-positive) and non-
bacteremic (culture-negative) SIRS patients at the time of hospital admission (D-1) and at the end of first week of the hospital stay (D-7). Data
are presented as means ± standard error of the mean of data from either 28 bacteremic or 24 non-bacteremic patients. *P < 0.05 vs non-
bacteremic patients at the same time point (Mann-Whitney test).
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biomarkers; unfortunately no data are available in the
middle of the follow up period.
Conclusions
sCD25 and IL-10 have been identified as reliable prog-
nostic tools in this context. Moreover, their diagnostic
accuracy could give a significant contribution to the
early identification of the patients with bacteremic SIRS.
The good prognostic performance of the SOFA score
has been confirmed.
Key messages
• IL-10 and sCD25 have emerged as valid prognostic
and early diagnostic tools in the clinical course of bac-
teremic SIRS.
• In particular sCD25 seems to be helpful for the
clinicians to monitor the patients admitted to the
Table 4 Performance of the studied variables in the diagnosis of bacteremic systemic inflammatory response
syndrome (SIRS)




IL-10 AUROCC 0.767 (0.601, 0.888) 0.753 (0.579, 0.883)
AUROCC significance P = 0.0021 P = 0.0016
Cutoff 3.05 0.59
Sensitivity 78.26 (56.3, 92.5) 66.67 (43.0, 85.4)
Specificity 80.0 (51.9, 95.7) 71.43 (41.9, 91.6)
Positive likelihood ratio 3.91 (2.8, 5.5) 2.33 (1.5, 3.7)
Negative likelihood ratio 0.27 (0.08, 1.0) 0.47 (0.2, 1.3)
sCD25 AUROCC 0.812 (0.544, 0.960) 0.785 (0.523, 0.943)
AUROCC significance P = 0.0095 P = 0.0201
Cutoff 19.9 22.1
Sensitivity 87.5 (47.3, 99.7) 87.5 (47.3, 99.7)
Specificity 75.0 (34.9, 96.8) 77.78 (40.0, 97.2)
Positive likelihood ratio 3.5 (2.2, 5.6) 3.94 (2.5, 6.1)
Negative likelihood ratio 0.17 (0.02, 1.5) 0.16 (0.02, 1.5)
IFN-g AUROCC 0.486 (0.266, 0.711) 0.745 (0.504, 0.910)
AUROCC significance P = 0.9204 P = 0.0342
Cut-off 9.0 1.8
Sensitivity 45.45 (16.7, 76.6) 60.0 (26.2, 87.8)
Specificity 70.0 (34.8, 93.3) 90.0 (55.5, 99.7)
Positive likelihood ratio 1.52 (0.7, 3.3) 6.0 (3.5, 10.4)
Negative likelihood ratio 0.78(0.3-2.3) 0.44 (0.06-3.3)
PCT AUROCC 0.800 (0.641, 0.911) 0.781(0.612, 0.901)
AUROCC significance P = 0.0001 P = 0.0011
Cutoff 0.24 0.32
Sensitivity 91.3 (72.0, 98.9) 95.24 (76.2, 99.9)
Specificity 62.5 (35.4, 84.8) 60.0 (32.3, 83.7)
Positive likelihood ratio 2.43 (1.6, 3.6) 2.38 (1.6, 3.6)
Negative likelihood ratio 0.14 (0.03, 0.6) 0.079 (0.01, 0.6)
CRP AUROCC 0.56 (0.392, 0.718) 0.58 (0.407, 740)
AUROCC significance P = 0.5276 P = 0.4055
Cutoff 137 125
Sensitivity 39.13 (19.7, 61.5) 50.0 (28.2, 71.8)
Specificity 87.5 (61.7, 98.4) 80.0 (51.9, 95.7
Positive likelihood ratio 3.13 (1.8, 5.4) 2.50 (1.5, 4.1)
Negative likelihood ratio 0.70 (0.2, 2.6) 0.62 (0.2, 1.9)
Diagnostic accuracy of IL-10, sCD25, IFN-g, procalcitonin (PCT) and C-reactive protein (CRP) evaluated by receiver-operating characteristics (ROC) analysis carried
out on samples obtained at the time of hospital presentation (D-1) and at the end of the first week of the hospital stay (D-7), to estimate the pro- and anti-
inflammatory mediators as diagnostic markers of bacteremic SIRS in critically ill patients. AUROCC, area under the ROC curve.
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Figure 4 Receiver-operating characteristic (ROC) analysis of diagnostic biomarkers. ROC curves for values of IL-10 (blue line), sCD25
(yellow line), IFN-g (red line), procalcitonin (PCT) (green line) and C-reactive protein (CRP) (orange line), observed in our patients stratified as
culture-positive or culture-negative (used as controls for ROC analysis), either at the time of hospital admission (D-1) (A) or at the end of first
week of the hospital stay (D-7) (B).
Figure 5 Serial measurements of procalcitonin (PCT) levels in the serum samples from bacteremic survivors and bacteremic
nonsurvivors. PCT levels were evaluated at 0, 24, 48, 72, and 168 h after admission. *P < 0.05 vs non-surviving bacteremic patients at the same
time point (Mann-Whitney test).
Table 5 Multivariate analysis of the factors associated with diagnosis of bacteremic patients with systemic
inflammatory response syndrome (SIRS)
Factor Odds ratio 95% (CI) P-value
IL-10 D-1 1.01 0.87, 1.16 > 0.05
D-7 0.97 0.70, 1.34 > 0.05
sCD25 D-1 1.11 0.97, 1.25 > 0.05
D-7 1.08 0.97, 1.22 > 0.05
IFN-g D-1 1.08 0.88, 1.32 > 0.05
D-7 0.40 0.12, 1.33 > 0.05
PCT D-1 3.86 0.16, 91.93 > 0.05
D-7 1.96 0.51, 7.61 > 0.05
CRP D-1 1.02 0.97, 1.05 > 0.05
D-7 0.95 0.89, 1.02 > 0.05
PCT: procalcitonin; CRP: C-reactive protein.
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hospital with signs of SIRS, and to address the early
therapeutic approach.
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